Albert Bourla, Pfizer CEO (Christopher Goodney/Bloomberg via Getty Images)
March 16, 2022 06:27 AM EDTUpdated 06:39 AM
FDA+
Coronavirus

Pfiz­er pitch­es 4th Covid-19 vac­cine shot for el­der­ly de­spite mixed da­ta from Is­rael

Amber Tong

The ball is now in the FDA’s court to de­cide whether to au­tho­rize a fourth dose of Pfiz­er and BioN­Tech’s Covid-19 vac­cine.

The two com­pa­nies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times